Find Funding Opportunities

Find Funding Opportunities

Subscribe to Find Funding OpportunitiesRSS
Filter By:
Returning 56 results

Notice of Special Interest (NOSI): Mentored Career Development Awards to Foster the Careers of Investigators Pursuing Research Related to Down syndrome as Part of the INCLUDE Project

Notice of Special Interest
Friday, December 6, 2019
Saturday, January 8, 2022
NOT-OD-20-021

Funding Opportunity Purpose

Notice Special Interest NOSI): Mentored Career Development Awards Foster Careers Investigators Pursuing Research Related Down syndrome Part the INCLUDE Project Notice Number: NOT-OD-20-021 Key Dates Release Date: December 6, 2019First Available Due Date:February 12, 2020 Expiration Date:January 08, 2022 Related Announcements NOT-OD-20-024 NOT-OD-20-023 NOT-OD-20-025 PA-19-126 Mentored Research Scientist Development Award Parent K01 - Independent Clinical Trial Allowed) PA-19-127 Mentored Research Scientist Development Award Parent K01 - Independent Clinical Trial Required) PA-19-084 Mentored Research Scientist Development Award Parent K01 Independent Basic Experimental Studies Humans Required) PA-19-116 Mentored Clinical Scientist Research Career Development Award Parent K08 Independent Clinical Trial Required) PA-19-117 Mentored Clinical Scientist Research Career Development Award Parent K08 Independent Clinical Trial Allowed) PA-19-086 Mentored Clinical Scientist Research Career Development Award Parent K08 Independent Basic Experimental Studies Humans Required) PA-19-118 Mentored Patient-Oriented Research Career Development Award Parent K23 Independent Clinical Trial Required) PA-19-119 Mentored Patient-Oriented Research Career Development Award Parent K23 – Independent Clinical Trial Allowed) PA-19-087 Mentored Patient-Oriented Research Career Development Award Parent K23 Independent Basic Experimental Studies Humans Required) PA-19-129 NIH Pathway Independence Award Parent K99/R00 Independent Clinical Trial Required) PA-19-130 NIH Pathway Independence Award Parent K99/R00 - Independent Clinical Trial Allowed) PA-19-090 NIH Pathway Independence Award Parent K99/R00 Independent Basic Experimental Studies Humans Required) NOT-OD-20-012 Notice Intent Publish Funding Opportunity Announcements Fiscal Year 2020 the INCLUDE INvestigation Co-occurring conditions across Lifespan Understand Down syndromE) Project RFA-OD-20-004 - INvestigation Co-occurring conditions across Lifespan Understand Down syndromE INCLUDE) Clinical Trial Readiness R21 Clinical Trial Allowed) RFA-OD-20-003 Clinical Trials Development Co-Occurring Conditions Individuals Down syndrome: Phased Awards INCLUDE R61/R33 Clinical Trial Required) RFA-OD-20-005 - Transformative Research Award the INCLUDE Investigation Co-occurring Conditions across Lifespan Understand Down syndrome) Project R01 Clinical Trial Allowed) RFA-OD-20-006 - Small Research Grants Analyses Down Syndrome-related Research Data the INCLUDE Project R03 Clinical Trial Allowed) RFA-OD-20-007 - Development the INCLUDE Investigation Co-occurring Conditions across Lifespan Understand Down syndromE) Project Data Coordinating Center U2C Clinical Trial Allowed) NOT-OD-20-022 Issued Office The Director, National Institutes Health OD) National Cancer Institute NCI) National Heart, Lung, Blood Institute NHLBI) National Human Genome Research Institute NHGRI) National Institute Aging NIA) National Institute Allergy Infectious Diseases NIAID) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Deafness Other Communication Disorders NIDCD) National Institute Dental Craniofacial Research NIDCR) National Institute Environmental Health Sciences NIEHS) National Institute Neurological Disorders Stroke NINDS) National Institute Nursing Research NINR) Purpose Background INvestigation Co-occurring conditions across Lifespan Understand Down syndromE INCLUDE) Project developed response Fiscal Year 2018 2019 Omnibus Appropriations Reports, encouraged NIH expand current efforts Down syndrome DS) common co-occurring conditions also seen the general population while increasing pipeline DS investigators. Information projects were funded in 2018 2019, well the INCLUDE Project Research Plan, available the INCLUDE Project website. Individuals DS face significant changing health challenges have often excluded participation research could improve health outcomes quality life. population understudied even though DS the most common genetic cause intellectual developmental disabilities IDD) and, the past 25 years, average lifespan doubled 30 60 years. addition intellectual disability, DS associated an increased prevalence autism epilepsy. 75% individuals DS experience cognitive decline a syndrome resembles Alzheimer’s disease, with onset decade two earlier typical Alzheimer’s disease. Individuals DS also high rates hearing loss, eye abnormalities, congenital heart defects, sleep apnea, pulmonary hypertension, gastrointestinal malformations, thyroid disease, leukemia, other autoimmune immune dysregulation disorders including celiac disease. However, people DS infrequently develop solid tumors such breast prostate cancer. Despite multiple risk factors coronary artery disease high rates obesity, sleep apnea, type 1 diabetes, people DS rarely develop atherosclerosis have myocardial infarctions. Understanding unique combination risk resiliencies inform medical advances individuals DS for individuals do have DS who share co-occurring conditions. Research Objectives Notice Special Interest NOSI) announces NIH support the professional development early career scientists aiming establish career DS-related research. providing scientists training, resources, mentorship, NIH intends foster pipeline investigators DS other intellectual disabilities will lead future research improve understanding the biology DS support development new treatments health conditions experienced those DS. NIH issuing NOSI expand community investigators conducting research related DS encouraging scientists physicians early their research careers develop research projects related co-occurring conditions associated DS. Sharing resources effective communication outputs the broader communities a high priority the INCLUDE Project. Applicants responding this NOSI strongly encouraged describe plans rapid sharing data results well innovative data analytics approaches Goal 3, NIH Strategic Plan Data Science). list of Funding Priorities Institute Center for project available the INCLUDE website. Applications response this NOSI should aligned the overall INCLUDE Project Research Plan, consists three components: Component 1: Targeted, high risk-high reward, basic science studies areas highly relevant Down syndrome Component 2: Cohort Study connect existing resources expand inclusion individuals Down syndrome Component 3: Inclusive clinical trials research co-occurring conditions individuals Down syndrome Projects propose recruit subjects DS encouraged promote enrollment research subjects the DS patient registry supported NIH, DS-Connect®. other data biospecimens human genetic non-genetic studies, awardees encouraged use biorepositories designated INCLUDE staff meet requirements broad sharing. NIH resource describing Common Data Elements may helpful during planning phases a project considering ways optimize data collection order facilitate broad data sharing.? Application Submission Information Notice applies due dates or after February 12, 2020 expires January 8, 2022. Applications response this NOSI must submitted using of following target Funding Opportunity Announcements FOAs) their reissued equivalents. Although all NIH components indicated above listed Participating Organizations all FOAs listed below, applications this special topic be accepted. Activity Code FOA First Available Due Date K01 PA-19-126 Mentored Research Scientist Development Award Parent K01 - Independent Clinical Trial Allowed) Feb 12, 2020 K01 PA-19-127 Mentored Research Scientist Development Award Parent K01 - Independent Clinical Trial Required) Feb 12, 2020 K01 PA-19-084 Mentored Research Scientist Development Award Parent K01 Independent Basic Experimental Studies Humans Required) Feb 12, 2020 K08 PA-19-116 Mentored Clinical Scientist Research Career Development Award Parent K08 Independent Clinical Trial Required) Feb 12, 2020 K08 PA-19-117 Mentored Clinical Scientist Research Career Development Award Parent K08 Independent Clinical Trial Allowed) Feb 12, 2020 K08 PA-19-086 Mentored Clinical Scientist Research Career Development Award Parent K08 Independent Basic Experimental Studies Humans Required) Feb 12, 2020 K23 PA-19-118 Mentored Patient-Oriented Research Career Development Award Parent K23 Independent Clinical Trial Required) Feb 12, 2020 K23 PA-19-119 Mentored Patient-Oriented Research Career Development Award Parent K23 – Independent Clinical Trial Allowed) Feb 12, 2020 K23 PA-19-087 Mentored Patient-Oriented Research Career Development Award Parent K23 Independent Basic Experimental Studies Humans Required) Feb 12, 2020 K99/R00 PA-19-129 NIH Pathway Independence Award Parent K99/R00 Independent Clinical Trial Required) Feb 12, 2020 K99/R00 PA-19-130 NIH Pathway Independence Award Parent K99/R00 - Independent Clinical Trial Allowed) Feb 12, 2020 K99/R00 PA-19-090 NIH Pathway Independence Award Parent K99/R00 Independent Basic Experimental Studies Humans Required Feb 12, 2020 instructions the SF424 R&R) Application Guide and listed funding opportunity announcements must followed, the following additions: funding consideration, applicants must include NOT-OD-20-021 in Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B not considered this initiative. Applications nonresponsive terms this NOSI be withdrawn consideration this initiative.   Inquiries Please direct inquiries the contacts Section VII the listed funding opportunity announcements the following additions/substitutions: list of contacts for participating NIH Institute Center available the INCLUDE website.    

Notice of Special Interest (NOSI): Ruth L. Kirschstein National Research Service Award (NRSA) Fellowship Awards to Support Training in Research Related to Down Syndrome as Part of the INCLUDE Project

Notice of Special Interest
Friday, December 6, 2019
Saturday, January 8, 2022
NOT-OD-20-020

Funding Opportunity Purpose

Notice Special Interest NOSI): Ruth L. Kirschstein National Research Service Award NRSA) Fellowship Awards Support Training Research Related Down Syndrome Part the INCLUDE Project Notice Number: NOT-OD-20-020 Key Dates Release Date: December 6, 2019 First Available Due Date: April 08, 2020 Expiration Date: January 08, 2022 Related Announcements NOT-OD-20-024 NOT-OD-20-023 NOT-OD-20-012 Notice Intent Publish Funding Opportunity Announcements Fiscal Year 2020 the INCLUDE INvestigation Co-occurring conditions across Lifespan Understand Down syndromE) Project PA-19-191 Ruth L. Kirschstein National Research Service Award NRSA) Individual Fellowship Students Institutions NIH-Funded Institutional Predoctoral Dual-Degree Training Programs Parent F30) PA-19-192 Ruth L. Kirschstein National Research Service Award NRSA) Individual Fellowship Students Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs Parent F30) PA-19-195 Ruth L. Kirschstein National Research Service Award NRSA) Individual Predoctoral Fellowship Parent F31) PA-19-196 Ruth L. Kirschstein National Research Service Award NRSA) Individual Predoctoral Fellowship Promote Diversity Health-Related Research Parent F31 - Diversity) PA-19-188 Ruth L. Kirschstein National Research Service Award NRSA) Individual Postdoctoral Fellowship Parent F32) RFA-OD-20-004 RFA-OD-20-003 RFA-OD-20-005 RFA-OD-20-006 RFA-OD-20-007NOT-OD-20-025 NOT-OD-20-022 Issued Office The Director, National Institutes Health OD) National Cancer Institute NCI) National Heart, Lung, Blood Institute NHLBI) National Human Genome Research Institute NHGRI) National Institute Aging NIA) National Institute Allergy Infectious Diseases NIAID) National Institute Arthritis Musculoskeletal Skin Diseases (NIAMS) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Deafness Other Communication Disorders NIDCD) National Institute Dental Craniofacial Research NIDCR) National Institute Environmental Health Sciences NIEHS) National Institute Neurological Disorders Stroke NINDS) National Institute Nursing Research NINR) Purpose Background INvestigation Co-occurring conditions across Lifespan Understand Down syndromE INCLUDE) Project developed response Fiscal Year 2018 2019 Omnibus Appropriations Reports, encouraged NIH expand current efforts Down syndrome DS) common co-occurring conditions also seen the general population while increasing pipeline DS investigators. Information projects were funded in 2018 2019, well the INCLUDE Project Research Plan?, available the INCLUDE Project website. Individuals DS face significant changing health challenges have often excluded participation research could improve health outcomes quality life. population understudied even though DS the most common genetic cause intellectual developmental disabilities IDD) and, the past 25 years, average lifespan doubled 30 60 years. addition intellectual disability, DS associated an increased prevalence autism epilepsy. 75% individuals DS experience cognitive decline a syndrome resembles Alzheimer’s disease, with onset decade two earlier typical Alzheimer’s disease. Individuals DS also high rates hearing loss, eye abnormalities, congenital heart defects, sleep apnea, pulmonary hypertension, gastrointestinal malformations, thyroid disease, leukemia, other autoimmune immune dysregulation disorders including celiac disease. However, people DS infrequently develop solid tumors such breast prostate cancer. Despite multiple risk factors coronary artery disease high rates obesity, sleep apnea, type 1 diabetes, people DS rarely develop atherosclerosis have myocardial infarctions. Understanding unique combination risk resiliencies inform medical advances individuals DS for individuals do have DS who share co-occurring conditions. Research Objectives Notice Special Interest NOSI) announces NIH support the professional development trainees aiming establish career DS-related research. providing scientists training, resources, mentorship, NIH intends foster pipeline investigators DS other intellectual disabilities will lead future research improve understanding the biology DS support development new treatments health conditions experienced those DS. Investigators early their careers e.g., predoctoral candidates) well those advanced degrees e.g., PhD, MD) benefit mentorship established investigators professionals the DS research community basic science fields well clinical translational arenas. NIH issuing NOSI expand community investigators conducting research related DS encouraging scientists physicians early their research careers develop research projects related co-occurring conditions associated DS. Sharing resources effective communication outputs the broader communities a high priority the INCLUDE Project. Applicants responding this NOSI strongly encouraged describe plans rapid sharing data results well innovative data analytics approaches Goal 3, NIH Strategic Plan Data Science). list of Funding Priorities Institute Center for project available the INCLUDE website. Applications response this NOSI should aligned the overall INCLUDE Project Research Plan, consists three components: Component 1: Targeted, high risk-high reward, basic science studies areas highly relevant Down syndrome Component 2: Cohort Study connect existing resources expand inclusion individuals Down syndrome Component 3: Inclusive clinical trials research co-occurring conditions individuals Down syndrome Projects propose recruit subjects DS encouraged promote enrollment research subjects the DS patient registry supported NIH, DS-Connect®. other data biospecimens human genetic non-genetic studies, awardees encouraged use biorepositories designated INCLUDE staff meet requirements broad sharing. NIH resource describing Common Data Elements may helpful during planning phases a project considering ways optimize data collection order facilitate broad data sharing. Application Submission Information Notice applies due dates or after April 8, 2020 expires January 8, 2022. Applications response this NOSI must submitted using of following target funding opportunity Announcements FOAs) their reissued equivalents. Although all NIH components indicated above listed Participating Organizations all FOAs listed below, applications this special topic be accepted. PA-19-191 Ruth L. Kirschstein National Research Service Award NRSA) Individual Fellowship Students Institutions NIH-Funded Institutional Predoctoral Dual-Degree Training Programs Parent F30) PA-19-192 Ruth L. Kirschstein National Research Service Award NRSA) Individual Fellowship Students Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs Parent F30) PA-19-195 Ruth L. Kirschstein National Research Service Award NRSA) Individual Predoctoral Fellowship Parent F31) PA-19-196 Ruth L. Kirschstein National Research Service Award NRSA) Individual Predoctoral Fellowship Promote Diversity Health-Related Research Parent F31 - Diversity) PA-19-188 Ruth L. Kirschstein National Research Service Award NRSA) Individual Postdoctoral Fellowship Parent F32) instructions the SF424 R&R) Application Guide and listed funding opportunity announcements must followed, the following addition: funding consideration, applicants must include NOT-OD-20-020 in Agency Routing Identifier field box 4b) the SF424 R&R form. Applications without information box 4b not considered this initiative. Applications nonresponsive terms this NOSI be be considered the NOSI initiative.   Inquiries Please direct inquiries the contacts Section VII the listed funding opportunity announcements the following additions/substitutions: list of contacts for participating NIH Institute Center available the INCLUDE website.    

Notice of Special Interest: Administrative Supplements for Research on Sexual and Gender Minority (SGM) Populations (Admin Supp Clinical Trial Optional)

Notice of Special Interest
Thursday, December 5, 2019
Tuesday, January 26, 2021
333
NOT-OD-20-032

Funding Opportunity Purpose

Notice Special Interest: Administrative Supplements Research Sexual Gender Minority SGM) Populations Admin Supp Clinical Trial Optional) Notice Number: NOT-OD-20-032 Key Dates Release Date: December 6, 2019 First Available Due Date: January 31, 2020 Expiration Date: January 26, 2021 nbsp; Related Announcements PA-18-591 Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) Issued National Institutes Health NIH) Sexual amp; Gender Minority Research Office SGMRO) National Center Complementary Integrative Health NCCIH) National Cancer Institute NCI) National Human Genome Research Institute NHGRI) National Heart, Lung, Blood Institute NHLBI) National Institute Aging NIA) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Allergy Infectious Diseases NIAID) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Drug Abuse NIDA) National Institute Deafness Other Communication Disorders NIDCD) National Institute Dental Craniofacial Research NIDCR) National Institute Diabetes Digestive Kidney Diseases NIDDK) National Institute Mental Health NIMH) National Institute Minority Health Health Disparities NIMHD) National Institute Neurological Disorders Stroke NINDS) National Institute Nursing Research NINR) Additionally, following NIH Offices co-fund applications assigned these Institutes Centers: Office Behavioral Social Sciences Research OBSSR) Office Research Women’s Health ORWH) Purpose mission the NIH to seek fundamental knowledge the nature behavior living systems the application that knowledge enhance health, lengthen life, reduce illness disability. NIH committed supporting research will increase scientific understanding the health wellbeing various population subpopulation groups that help establish effectiveness evidence-based health interventions services individuals within groups. NIH places high priority research populations appear have distinctive health risk profiles who also received insufficient attention investigators. this end, Notice Special Interest NOSI) announces availability administrative supplements provide funding the expansion existing research projects incorporate sexual gender minority SGM) populations, include, are limited to, those populations described Notice NOT-OD-19-139. Basic, social, behavioral, clinical, translational, health services research relevant the missions the sponsoring NIH Institutes Centers ICs) be proposed response this solicitation. Potential applicants also encouraged review the FY 2017 Portfolio Analysis of NIH-funded SGM research identify potential research gaps may relevant this NOSI. Background Although collective knowledge base SGM health grown substantially since release the 2011 Institute Medicine the National Academy Medicine) report on health lesbian, gay, bisexual, transgender people, continually growing body evidence indicates SGM individuals still suffer disproportionately numerous conditions, diseases, health issues compared the general population. October 2016, the National Institute Minority Health Health Disparities, collaboration the Agency Healthcare Research Quality, announced that SGMs been officially designated health disparity population. designation facilitated creation tailored research projects, programs, activities, funding opportunities tackle unique health-related issues encountered SGM individuals. addition, ascertainment SGM status ongoing planned population studies been enhanced. However, SGM-specific health disparities persist today, there still urgent need novel strategies understand, measure, address, prevent them. of August 28, 2019, NIH definition sexual gender minorities" includes, is limited to, individuals identify lesbian, gay, bisexual, asexual, transgender, two-spirit, queer, and/or intersex. Individuals same-sex gender attractions behaviors those a difference sex development also included. populations also encompass those do self-identify one these terms whose sexual orientation, gender identity expression, reproductive development characterized non-binary constructs sexual orientation, gender, and/or sex. Applicants this administrative supplement propose study relevant SGM subpopulations explicitly identified this definition and/or adopt classification frameworks terminologies appropriate. Specific Areas Research Interest NOSI calls research will enrich scientific understanding how sexual orientation, gender identity, and/or being born disorders/differences sex development intersex conditions relate health outcomes, health risks, health behaviors, perceptions expectations health, access health-related services associated barriers. Appropriate topics studies these supplements include, are limited to, those listed below: Addition SGM participants an ongoing study either not originally include or not enrolled enough SGM participants make meaningful comparisons between groups; proposed studies must sufficiently powered allow meaningful comparisons Expansion an ongoing study focused one SGM group add another; proposed studies must sufficiently powered allow meaningful comparisons Expansion surveys questionnaires add items related sexual attraction, sexual behavior, sexual identity, gender identity, gender expression, and/or non-binary sex relevant appropriate Assessment reliability and/or validity measures relevant sexual attraction, sexual behavior, sexual identity, gender identity, gender expression, and/or non-binary sex Methodological strategic innovations improve recruitment retention SGM individuals any research activity Ethical, legal, social science research the implications data collection and/or research findings SGM populations Scope Support Administrative supplements be used meet increased costs are within scope the approved parent award, that unforeseen the new renewal application grant progress report non-competing continuation support submitted. Applicants this NOSI should propose research that, successful, contribute a greater understanding the health wellbeing SGM communities. Clinical trials cannot proposed be added grants do include clinical trial since would constitute change scope. IC-Specific Considerations applications submitted response this NOSI should fall within mission the IC the awarded parent grant. Applicants strongly encouraged discuss proposed supplement project the IC Program Officer the funded parent award prior submission a supplement application order ensure the proposed activity aligns the scientific priorities the IC is within scope the parent award. Scientific inquiries also addressed the contacts listed the Inquiries section below. Information   Recently issued trans-NIH policy notices may affect application submission. full list policy notices published NIH provided the NIH Guide Grants Contracts. awards subject the terms conditions, cost principles, other considerations described the NIH Grants Policy Statement. Authority Regulations Awards made under authorization Sections 301 405 the Public Health Service Act amended 42 USC 241 284) under Federal Regulations 42 CFR Part 52 45 CFR Part 75. Application Submission Information Applications this initiative must submitted using following opportunity its subsequent reissued equivalent: PA-18-591 - Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) instructions the SF424 R&R) Application Guide and PA-18-591 must followed the following additions: Application Due Dates – January 31, 2020 FY 2020, January 25, 2021 FY 2021, 5:00 PM local time applicant organization. expiration date January 26, 2021. project budget periods must within currently approved project period the existing parent award. funding consideration, applicants must include ldquo;NOT-OD-20-032” without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B not considered this initiative. Requests be one year support only. project budget cannot exceed 100,000 total costs. Research Strategy section the application limited 6 pages. process Streamlined Submissions using eRA Commons cannot used this initiative. Applicants strongly encouraged notify Program Officer the IC supporting parent award a request been submitted response this NOSI order facilitate efficient processing the application. Applications do comply these instructions be delayed not accepted review. Applications nonresponsive terms this NOSI be be considered the NOSI initiative. Inquiries Please direct inquiries the Program Officer associated the parent award and/or designated contact the IC supporting parent award listed below: Scientific/Research Contact(s) Della White, PhD National Center Complementary Integrative Health NCCIH) Telephone: 301-827-6358 whitede@mail.nih.gov Liz Perruccio, PhD National Cancer Institute NCI) Telephone: 240-276-6178 Email: perruccioem@mail.nih.gov Tina Gatlin, PhD National Human Genome Research Institute NHGRI) Telephone: 301-?480-2280 Email: gatlincl@mail.nih.gov Brad Newsome, PhD National Heart, Lung, Blood Institute NHLBI) Telephone: 301-827-8170 Email: brad.newsome@nih.gov Melissa Gerald, PhD National Institute Aging NIA) Telephone: 301-?496-3136 Email: melissa.gerald@nih.gov Robert Freeman, PhD National Institute Alcohol Abuse Alcoholism NIAAA) Telephone: 301-443-8820 Email: rfreeman@mail.nih.gov Philip Renzullo, PhD, MPH National Institute Allergy Infectious Diseases NIAID) Telephone: 240-627-3041 Email: prenzullo@mail.nih.gov Heiyoung Park, PhD National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) Telephone: 301-594-5032 Email: parkh1@mail.nih.gov Jeffrey Schulden, MD National Institute Drug Abuse NIDA) Telephone: 301-402-1526 Email: schuldenj@mail.nih.gov Alberto Rivera-Rentas, PhD National Institute Deafness Other Communication Disorders NIDCD) Telephone: 301-496-1804 Email: riverara@mail.nih.gov Elise Rice, PhD National Institute Dental Craniofacial Research NIDCR) Telephone: 301-594-4814 Email: elise.rice@nih.gov Tamara Bavendam, MD, MS National Institute Diabetes Digestive Kidney Diseases NIDDK) Telephone: 301-594-4733 Email: bavendamtg@mail.nih.gov Tamara Lewis Johnson, MPH, MBA National Institute Mental Health NIMH) Telephone: 301-594-7963 Email: tl247e@nih.gov Jennifer Alvidrez, PhD National Institute Minority Health Health Disparities NIMHD) Telephone: 301-594-9567 Email: alvidrezjl@mail.nih.gov Richard Benson, MD, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-9135 Email: richard.benson@nih.gov Rebecca Henry, PhD, BSN, RN National Institute Nursing Research NINR) Telephone: 301-594-5976 Email: rebecca.henry@nih.gov Rajasri Roy, PhD, MPH Office Research Women’s Health ORWH) Telephone: 301-451-0993 Email: royr2@mail.nih.gov nbsp;

Notice of Special Interest: Advancing Research for Tickborne Diseases (TBDs)

Notice of Special Interest
Tuesday, November 12, 2019
Sunday, January 8, 2023
NOT-AI-20-005

Funding Opportunity Purpose

Notice Special Interest: Advancing Research Tickborne Diseases TBDs) Notice Number: NOT-AI-20-005 Key Dates Release Date: November 12, 2019 First Available Due Date: January 05, 2020 Expiration Date: January 08, 2023 Related Announcements PA-19-055 NIH Research Project Grant Parent R01 Clinical Trial Required) PA-19-056 NIH Research Project Grant Parent R01 Clinical Trial Allowed) PA-19-270 PHS 2019-02 Omnibus Solicitation the NIH Small Business Technology Transfer Grant Applications Parent STTR R41/R42] Clinical Trial Allowed) PA-19-272 PHS 2019-02 Omnibus Solicitation the NIH, CDC, FDA Small Business Innovation Research Grant Applications Parent SBIR R43/R44] Clinical Trial Allowed) PAR-19-134 Research Enhancement Award Program REAP) Health Professional Schools Graduate Schools R15 Clinical Trial Allowed) Issued National Institute Allergy Infectious Diseases NIAID ) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Mental Health NIMH ) National Institute Neurological Disorders Stroke NINDS) National Center Complementary Integrative Health NCCIH ) Purpose purpose this Notice to announce the National Institute Allergy Infectious Diseases NIAID), National Institute Arthritis Musculoskeletal Skin Diseases NIAMS), National Institute Mental Health NIMH), National Institute Neurological Disorders Stroke NINDS), the National Center Complementary Integrative Health NCCIH) encourage new applications advance research activities relevant the five strategic priorities identified the recently released NIH Strategic Plan Tickborne Disease Research: Improve fundamental knowledge TBDs to understand host, vector, pathogen factors drive TBD pathogenesis transmission. Elucidate host immune mechanisms response and exploited TBD pathogens. Advance research improve diagnosis TBDs using both host- pathogen-targeted approaches, including research rapid diagnostics multiplex platform approaches detect multiple tickborne pathogens. Accelerate research improve TBD prevention by supporting science design, develop, evaluate vaccines, vector control strategies, other prevention approaches. Promote research improve treatment all forms TBDs, including studies develop effective therapies treat symptoms persist after TBD treatment, therapies non-infectious TBDs, new antimicrobials. Support tools resources advance research understanding, preventing, diagnosing, treating TBDs, including repositories, genomic resources, animal models, preclinical services aid development assessment diagnostic, vaccine, therapeutic candidates. NIAID: NIAID support research the biology tickborne pathogens, vectors, animal reservoirs, human hosts, the interactions among elements they help understand underlying causes human disease. NIAID interested applications the basic science behind tickborne infections in applications seeking develop new approaches prevent, diagnose, treat those infections. NIAID also support research non-infectious TBDs, particularly alpha-gal syndrome. focus research this syndrome to understand pathogenesis develop improved diagnostics therapeutic approaches. NIAMS : NIAMS interested supporting research studies human immunity its role the initiation propagation Lyme arthritis. of systems biology approaches identify critical cellular molecular pathways involved pathogenesis encouraged. interests include studies the joint tissue remodeling pathways the cross-talk a wide range hematopoietic other cell types Lyme arthritis. Please note, NIAMS only accepts mechanistic studies meet NIH's definition a clinical trial PA-19-055. NIMH: As lead federal agency research mental disorders, NIMH interested the following areas: Basic mechanistic neuroscience studies persistent effects Lyme disease brain signaling, circuits, proximal effects functional processes such cognition are impaired mental illnesses. Research illuminate mechanisms which tick-borne diseases lead specific psychiatric complications. Research understand neurobiological basis the impact tick-borne diseases specific domains functions relevant mental health, informed the Research Domain Criteria RDoC) approach. Research decrease burden acute chronic psychiatric complications Lyme disease other tick-borne diseases. Please note, NIMH only accepts mechanistic studies meet NIH's definition a clinical trial PA-19-055. NINDS : NINDS interested supporting research the basic biology mechanisms the neurological consequences tick-borne diseases. includes developing animal cell models will facilitate studying nervous system pathogenesis these diseases developing new approaches diagnose treat neurological complications. Please note, NINDS only accepts mechanistic studies meet NIH's definition a clinical trial PA-19-055. NCCIH: NCCIH support research the mechanisms which complementary integrative health approaches improve tick-borne disease TBD) treatment and/or post-TBD symptom care. Complementary integrative approaches include mind/brain-focused practices i.e., meditation, hypnosis), body-based approaches i.e., acupuncture, massage, spinal manipulation), meditative exercise i.e., yoga, tai chi, qi gong), natural products i.e., botanicals, dietary supplements, probiotics), isolation in combination conventional medical treatments. NCCIH not accept clinical trial measures efficacy effectiveness any intervention through NOSI. NCCIH only accepts mechanistic studies meet NIH's definition a clinical trial PA-19-055. Application Submission Information notice applies due dates or after January 5, 2020 subsequent receipt dates through January 8, 2023. Submit applications this initiative using of following funding opportunity announcements FOAs) any reissues these announcement through expiration date this notice. PA-19-055 NIH Research Project Grant Parent R01 Clinical Trial Required) PA-19-056 NIH Research Project Grant Parent R01 Clinical Trial Allowed) PA-19-270 PHS 2019-02 Omnibus Solicitation the NIH Small Business Technology Transfer Grant Applications Parent STTR R41/R42] Clinical Trial Allowed) PA-19-272 PHS 2019-02 Omnibus Solicitation the NIH, CDC, FDA Small Business Innovation Research Grant Applications Parent SBIR R43/R44] Clinical Trial Allowed) PAR-19-134 Research Enhancement Award Program REAP) Health Professional Schools Graduate Schools R15 Clinical Trial Allowed) instructions the SF424 R&R) Application Guide and funding opportunity announcement used submission must followed, the following additions: funding consideration, applicants must include ldquo;NOT-AI-20-005” without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B not considered this initiative. Applications nonresponsive terms this NOSI be be considered the NOSI initiative. Inquiries Please direct inquiries to: Samuel Perdue, Ph.D. National Institute Allergy Infectious Diseases NIAID) Telephone: 240-627-3341 E-mail: sperdue@nih.gov Yisong Wang, PhD. National Center Complementary Integrative Health NCCIH) Telephone: 301-480-9483 E-mail: yisong.wang@nih.gov Su-Yau Mao, Ph.D. National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) Telephone: 301-594-5032 Email: maos2@mail.nih.gov Sarah H. Lisanby, M.D.. National Institute Mental Health NIMH) Telephone: 301-451-3029 Email: lisanbysh@mail.nih.gov Wong, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1431 Email: wongm@ninds.nih.gov

Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)

PAS
Thursday, July 18, 2019
Translational Research, Clinical Trials Research
Wednesday, September 7, 2022
R41/R42
PAS-19-317

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) invites applications to NIA's Small Business Technology Transfer Research (STTR) program to conduct research leading to the development of innovative products and/or services that may advance progress in preventing and treating Alzheimer's disease (AD) and Alzheimer's-disease-related dementias (ADRD) and/or caring for and treating AD/ADRD patients.

Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional)

PAS
Thursday, July 18, 2019
Translational Research, Clinical Trials Research
Wednesday, September 7, 2022
R43/R44
PAS-19-316

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) invites applications to NIA's Small Business Innovation Research (SBIR) program to conduct research leading to the development of innovative products and/or services that may advance progress in preventing and treating Alzheimer's disease (AD) and Alzheimer's-disease-related dementias (ADRD) and/or caring for and treating AD/ADRD patients.

Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)

PAR
Wednesday, May 8, 2019
Sunday, May 8, 2022
R03
PAR-19-276

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) encourages investigators to submit research grant applications that will identify, develop, test, evaluate and/or refine strategies to disseminate and implement evidence-based practices (e.g. behavioral interventions; prevention, early detection, diagnostic, treatment and disease management interventions; quality improvement programs) into public health, clinical practice, and community settings. In addition, studies to advance dissemination and implementation research methods and measures are encouraged.

PHS 2019-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed

PA
Tuesday, May 7, 2019
Tuesday, July 7, 2020
R43/R44
PA-19-272

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH, CDC, and FDA awarding components identified in this FOA are encouraged to submit SBIR grant applications in response to identified topics (see PHS 2019-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA. This Parent Funding Opportunity Announcement does not accept clinical trials.

BRAIN Initiative: Tools to Facilitate High-Throughput Microconnectivity Analysis (R01 Clinical Trial Not Allowed)

RFA
Monday, April 8, 2019
Thursday, October 1, 2020
R01
RFA-MH-20-135

Funding Opportunity Purpose

The purpose of this Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is to encourage applications that will develop and validate tools and resources to facilitate the detailed analysis of brain microconnectivity. Novel and augmented techniques are sought that will ultimately be broadly accessible to the neuroscience community for the interrogation of microconnectivity in healthy and diseased brains of model organisms and humans. Development of technologies that will significantly drive down the cost of connectomics would enable routine mapping of the microconnectivity on the same individuals that have been analyzed physiologically, or to compare normal and pathological tissues in substantial numbers of multiple individuals to assess variability. Advancements in both electron microscopy (EM) and super resolution light microscopic approaches are sought. Applications that propose to develop approaches that break through existing technical barriers to substantially improve current capabilities are highly encouraged. Proof-of-principle demonstrations and/or reference datasets enabling future development are welcome, as are improved approaches for automated segmentation and analysis strategies of neuronal structures in EM images.no

Institutional Translational Research Training Program (T32)

PAR
Friday, March 22, 2019
Thursday, May 27, 2021
T32
PAR-19-228

Funding Opportunity Purpose

The purpose of the NINDS Institutional Translational Research Training Program is to equip trainees with the knowledge and skills needed to advance basic research toward clinical application. These programs will support, students and/or postdocs conducting basic, disease-relevant research in an environment that includes 1) basic neuroscientists and clinicians who are actively engaged in collaborative research projects, 2) neuroscience researchers with expertise in translational processes who are conducting research designed to move basic discoveries toward clinical application and 3) relationships with industry and government regulatory agencies. Programs will have a cohesive educational approach to translational training in areas relevant to the NINDS mission, and in which students and postdocs learn the processes involved in translational research in the context of their individual projects. Programs supported by this FOA must include activities that ensure a thorough understanding of experimental design, strong statistical and analytical skills, and skills for communicating science with a wide variety of audiences. These programs are intended to be 2 years in duration and support training of one or more of the following groups: advanced predoctoral students, postdoctoral fellows and fellowship-stage clinicians. Upon completion of the program, trainees will be prepared to address basic research problems with an understanding of the requirements for translating discoveries into viable therapies.

Pages